Near real-time quantification of microbial volatile organic compounds from mycoparasitic fungi: Potential for advanced monitoring and pest control.

Microbial volatile organic compounds (MVOCs) are thought to play a key role in the interactions between mycoparasitic fungi, such as the biocontrol agent Trichoderma atroviride (T. atroviride), and their environment. However, the analysis of MVOC emissions from fungal samples is challenging because of low analyte concentrations, typically in the ppbV-range, and the complex chemical nature of biological samples. In a recent study using proton transfer reaction-time of flight-mass spectrometry (PTR-ToF-MS) to determine MVOC emissions from T. atroviride, many product ions were unspecific, as they could arise from a large number of possible analytes. The aim of the present study was to determine whether fast gas chromatography (fast-GC) coupled to PTR-ToF-MS could be used to overcome this issue and constitute a suitable on-line, near real-time method to identify and quantify fungal MVOC emissions in the ppbV-to-ppmV regime. Using gas standards of eleven MVOCs known to be emitted by T. atroviride such as 6-amyl-α-pyrone (6-PP), 2-pentylfuran, 1-octen-3-ol, 2-heptanone, 3-octanone, 2-methyl-1-propanol, 2-pentanone, 3-methyl-1-butanol, 3-methylbutanal, acetone and ethanol, we developed a fast-GC method with a total runtime of 180 s which significantly enhances the analytical specificity of PTR-ToF-MS compared to conventional PTR-ToF-MS without fast-GC separation. Limits of detection were on the order of 0.1-4 ppbV. The increased analytical specificity demonstrated notable benefits, especially for MVOCs having partially overlapping distributions of product ions when analyzed directly using PTR-ToF-MS. In order to demonstrate the applicability of the analytical method, we analysed T. atroviride samples in four biological replicates twice daily over a duration of five days. Using the fast-GC method, nine out of the eleven MVOC species considered in this study in the headspace of T. atroviride could be identified and quantified and their time evolution over the five-day incubation period determined. The measured volume mixing ratios (VMRs) ranged from single-digit ppbV (2-pentylfuran) up to few ppmV (6-PP and ethanol), with the other compounds in the 10-to-100-ppbV range (1-octen-3-ol, 2-heptanone, 2-methyl-1-propanol, 3-methyl-1-butanol, 3-methylbutanal and acetone). Our results suggest that fast-GC-PTR-ToF-MS is a method well-suited for the analysis of gas-phase samples of biological origin, including but not limited to (mycoparasitic) fungi, in a wide range of VMRs from sub-ppbV to few-ppmV.

Establishing a cell-based screening workflow for determining the efficiency of CYP2C9 metabolism: moving towards the use of breath volatiles in personalised medicine.

The use of volatile biomarkers in exhaled breath as predictors to individual drug response would advance the field of personalised medicine by providing direct information on enzyme activity. This would result in enormous benefits, both for patients and for the healthcare sector. Non-invasive breath tests would also gain a high acceptance by patients. Towards this goal, differences in metabolism resulting from extensive polymorphisms in a major group of drug-metabolizing enzymes, the cytochrome P450 (CYP) family, need to be determined and quantified. CYP2C9 is responsible for metabolising many crucial drugs (e.g., diclofenac) and food ingredients (e.g., limonene). In this paper, we provide a proof-of-concept study that illustrates thein vitrobioconversion of diclofenac in recombinant HEK293T cells overexpressing CYP2C9 to 4'-hydroxydiclofenac. Thisin vitroapproach is a necessary and important first step in the development of breath tests to determine and monitor metabolic processes in the human body. By focusing on the metabolic conversion of diclofenac, we have been able to establish a workflow using a cell-based system for CYP2C9 activity. Furthermore, we illustrate how the bioconversion of diclofenac is limited in the presence of limonene, which is another CYP2C9 metabolising substrate. We show that increasing limonene levels continuously reduce the production of 4'-hydroxydiclofenac. Michaelis-Menten kinetics were performed for the diclofenac 4'-hydroxylation with and without limonene, giving a kinetic constant of the reaction,KM, of 103µM and 94.1µM, respectively, and a maximum reaction rate,Vmax, of 46.8 pmol min-1106cells-1and 56.0 pmol min-1106cells-1with and without the inhibitor, respectively, suggesting a non-competitive or mixed inhibition type. The half-maximal inhibitory concentration value (IC50) for the inhibition of the formation of 4'-hydroxydiclofenace by limonene is determined to be 1413µM.